Beauty Health (NASDAQ:SKIN – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.
Several other brokerages have also recently weighed in on SKIN. TD Cowen reduced their price objective on shares of Beauty Health from $1.65 to $1.50 and set a “hold” rating on the stock in a research note on Monday. Canaccord Genuity Group reaffirmed a “hold” rating and set a $1.50 target price on shares of Beauty Health in a research report on Friday, March 13th. Jefferies Financial Group reaffirmed a “hold” rating and set a $1.60 target price on shares of Beauty Health in a report on Wednesday, January 14th. Finally, Benchmark reiterated a “hold” rating on shares of Beauty Health in a research report on Friday, March 13th. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $2.42.
Get Our Latest Stock Analysis on Beauty Health
Beauty Health Stock Up 0.9%
Beauty Health (NASDAQ:SKIN – Get Free Report) last posted its earnings results on Thursday, March 12th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Beauty Health had a negative net margin of 3.16% and a negative return on equity of 15.40%. The firm had revenue of $82.37 million for the quarter, compared to analyst estimates of $78.07 million. On average, research analysts anticipate that Beauty Health will post -0.25 earnings per share for the current year.
Institutional Investors Weigh In On Beauty Health
A number of institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Beauty Health during the third quarter worth $26,000. Franklin Resources Inc. bought a new position in Beauty Health during the third quarter worth $31,000. Zacks Investment Management acquired a new position in Beauty Health in the third quarter valued at $35,000. Ameriprise Financial Inc. acquired a new position in Beauty Health in the third quarter valued at $38,000. Finally, Atom Investors LP bought a new stake in Beauty Health during the fourth quarter valued at $29,000. 93.26% of the stock is owned by institutional investors.
Beauty Health Company Profile
Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.
Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.
See Also
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
